Literature DB >> 29106683

Neural Responses to Smoking Cues in Schizophrenia.

Lauren V Moran1, Jennifer M Betts1, Dost Ongur1, Amy C Janes1.   

Abstract

The high prevalence of nicotine dependence contributes to excess mortality in schizophrenia. Cue reactivity, or the encounter of drug-related cues or contexts, triggers craving, drug-seeking, and relapse. Prior functional magnetic resonance imaging (fMRI) research indicates that individuals with schizophrenia have blunted neural responses to rewarding stimuli in association with more severe negative symptoms. The objectives of this study are to determine if smokers with schizophrenia have altered neural reactivity to smoking cues compared with non-psychiatrically ill smokers and to evaluate the influence of negative symptoms on cue reactivity. Twenty smokers with schizophrenia and 19 control smokers underwent fMRI while viewing smoking-related and neutral cues. The primary analysis was group comparison of Smoking-Neutral contrast using whole-brain analysis (Pcorrected < .05). Smokers with schizophrenia had significantly greater baseline carbon monoxide levels and longer duration of smoking, suggesting more nicotine use. While both groups had greater brain reactivity to smoking vs neutral cues, smokers with schizophrenia had significantly decreased cue reactivity (Smoking-Neutral) compared to controls in bilateral frontal midline regions. There were significant negative correlations between negative symptoms and frontal midline reactivity. Despite greater nicotine use, smokers with schizophrenia exhibited decreased smoking cue-induced neural reactivity in frontal midline regions, suggesting that increased smoking and low cessation rates in schizophrenia are not primarily driven by responses to smoking-related cues. The finding of negative correlations between cue reactivity and negative symptoms is consistent with previous research demonstrating decreased neural responses to rewarding cues, particularly in patients with negative symptoms.

Entities:  

Mesh:

Year:  2018        PMID: 29106683      PMCID: PMC5890466          DOI: 10.1093/schbul/sbx085

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  60 in total

1.  Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings.

Authors:  L S Cox; S T Tiffany; A G Christen
Journal:  Nicotine Tob Res       Date:  2001-02       Impact factor: 4.244

2.  Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort.

Authors:  Jussi Mäkinen; Jouko Miettunen; Erika Jääskeläinen; Juha Veijola; Matti Isohanni; Hannu Koponen
Journal:  Psychiatry Res       Date:  2010-05-16       Impact factor: 3.222

3.  Brain circuits that link schizophrenia to high risk of cigarette smoking.

Authors:  Lauren V Moran; Hemalatha Sampath; Peter Kochunov; L Elliot Hong
Journal:  Schizophr Bull       Date:  2012-12-12       Impact factor: 9.306

4.  Nicotine and familial vulnerability to schizophrenia: a discordant twin study.

Authors:  Michael J Lyons; Jessica L Bar; William S Kremen; Rosemary Toomey; Seth A Eisen; Jack Goldberg; Stephen V Faraone; Ming Tsuang
Journal:  J Abnorm Psychol       Date:  2002-11

5.  Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program.

Authors:  Monica C Mann-Wrobel; Melanie E Bennett; Elaine E Weiner; Robert W Buchanan; M Patricia Ball
Journal:  Schizophr Res       Date:  2010-11-26       Impact factor: 4.939

6.  Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.

Authors:  Sunny J Dutra; Luke E Stoeckel; Sara V Carlini; Diego A Pizzagalli; A Eden Evins
Journal:  Psychopharmacology (Berl)       Date:  2011-06-22       Impact factor: 4.530

7.  Memory retrieval of smoking-related images induce greater insula activation as revealed by an fMRI-based delayed matching to sample task.

Authors:  Amy C Janes; Robert S Ross; Stacey Farmer; Blaise B Frederick; Lisa D Nickerson; Scott E Lukas; Chantal E Stern
Journal:  Addict Biol       Date:  2013-11-22       Impact factor: 4.280

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Increased ventro-medial prefrontal activations in schizophrenia smokers during cigarette cravings.

Authors:  Stéphane Potvin; Ovidiu Lungu; Olivier Lipp; Pierre Lalonde; Vessela Zaharieva; Emmanuel Stip; Jean-Pierre Melun; Adrianna Mendrek
Journal:  Schizophr Res       Date:  2016-03-19       Impact factor: 4.939

10.  Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine.

Authors:  Isabelle Boileau; Alain Dagher; Marco Leyton; Krzysztof Welfeld; Linda Booij; Mirko Diksic; Chawki Benkelfat
Journal:  J Neurosci       Date:  2007-04-11       Impact factor: 6.167

View more
  1 in total

1.  Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence.

Authors:  Heather Burrell Ward; Adam Beermann; Uzma Nawaz; Mark A Halko; Amy C Janes; Lauren V Moran; Roscoe O Brady
Journal:  Front Psychiatry       Date:  2022-01-27       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.